• DOI:10.1002/ijc.28696
Corpus ID: 22657446

Serotype chimeric oncolytic adenovirus coding for GM‐CSF for treatment of sarcoma in rodents and humans

@article{Bramante2014SerotypeCO,
  title={Serotype chimeric oncolytic adenovirus coding for GM‐CSF for treatment of sarcoma in rodents and humans},
  author={Simona Bramante and A. Koski and A. Kipar and I. Diaconu and Ilkka Liikanen and O. Hemminki and L. Vassilev and S. Parviainen and V. Cerullo and S. Pesonen and M. Oksanen and Raita Heiskanen and Noora Rouvinen-Lagerstr{\"o}m and Maiju Merisalo-Soikkeli and T. Hakonen and T. Joensuu and A. Kanerva and A. Hemminki},
  journal={International Journal of Cancer},
  year={2014},
  volume={135}
}

Simona Bramante, A. Koski, +16 authors A. Hemminki

Published 2014

Medicine

International Journal of Cancer

Sarcomas are a relatively rare cancer, but often incurable at the late metastatic stage. Oncolytic immunotherapy has gained attention over the past years, and a wide range of oncolytic viruses have been delivered via intratumoral injection with positive safety and promising efficacy data. Here, we report preclinical and clinical results from treatment of sarcoma with oncolytic adenovirus Ad5/3‐D24‐GMCSF (CGTG‐102). Ad5/3‐D24‐GMCSF is a serotype chimeric oncolytic adenovirus coding for human… CONTINUE READING

View on Wiley

hi.helsinki.fi

Save to Library

Create Alert

Cite

Launch Research Feed